Drug Trial Radar · NCT06089330
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Oct 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
102
Planned (sponsor's estimate)
Start
Jan 2024
Primary completion
Jul 2024
Study completion Dec 2024
Sponsor
- Lead sponsor
- Shanghai JMT-Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a phase Ⅱ, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with Irinotecan and SG001 in Patients with Metastatic Colorectal Cancer (mCRC).
Conditions
- Metastatic Colorectal Cancer (mCRC)
Interventions
JMT101Drug
JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
SG001Drug
240 mg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
IrinotecanDrug
180mg/m\^2, IV infusion once every two weeks (one treatment cycle is 4 weeks).
Regorafenib (Stivarga)Drug
160 mg, taken orally once daily for the first 21 days of each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT)Time frame: After1 cycle of treatment of the safety run-in phase patients (each cycle is 28 days)
- Overall response rate (ORR)Time frame: Up to approximately 2 years
- Incidence and severity of adverse events (AE) and serious adverse events (SAE)Time frame: Up to approximately 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.